Brief: Single Infusion Of Carvykti Delivered Five-Year Treatment-Free Remissions In 50% Of Patients In Early Line Relapsed/Refractory Multiple Myeloma
25/09/2026 12:02
BRIEF-Single Infusion Of Carvykti Delivered Five-Year Treatment-Free Remissions In 50% Of Patients In Early Line Relapsed/Refractory Multiple Myeloma Sept 25 (Reuters) - Johnson & Johnson JNJ.N:
SINGLE INFUSION OF CARVYKTI® (CILTACABTAGENE AUTOLEUCEL) DELIVERED FIVE-YEAR TREATMENT-FREE REMISSIONS IN 50% OF PATIENTS IN EARLY LINE RELAPSED/REFRACTORY MULTIPLE MYELOMA
J&J - CARVYKTI DELIVERS FIVE-YEAR TREATMENT-FREE REMISSIONS IN 50% OF EARLY LINE RRMM PATIENTS
J&J - FIVE-YEAR OVERALL SURVIVAL RATE 69.2%, MEDIAN PROGRESSION-FREE SURVIVAL 60.5 MONTHS
Source text: ID:nPn3mrJ6ka
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Johnson & Johnson
See all newsEli Lilly hits record high as healthcare stocks rally
Kenvue loses bid for rehearing after Tylenol autism lawsuits revived (updated)
Brief: Johnson & Johnson Announces New Data For Tremfya
Kenvue loses bid for rehearing after Tylenol autism lawsuits revived
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin